Endo Diversifies Further With Purchase Of Qualitest for $1.2 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
By buying the sixth-largest generics firm in the U.S. Endo gets what it says is critical mass in the U.S. generics market and significant domestic manufacturing capability.